[Editorial] Cancer drug safety: time to re-focus on tackling adverse effects

Drug safety is once again under the spotlight. In a study presented at the European Society of Medical Oncology Congress (Oct 7–11, 2016; Copenhagen, Denmark), Paolo Bossi and colleagues showed that a substantial number of clinical trials testing targeted and immunotherapies have suboptimal reporting of adverse events, particularly with regards to recurrent or late toxicities. Additionally, the US Food and Drug Administration (FDA) announced on Oct 4, 2016, that 27 drugs and drug classes—several of which include cancer agents—have been put on their watch list because of worrying evidence of unacceptable adverse events.

http://ift.tt/2f6L3Ki